About MIRA Pharmaceuticals, Inc.
https://mirapharmaceuticals.comMIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.
CEO
Erez Aminov
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
CROSS STAFF INVESTMENTS INC
Shares:359.4K
Value:$531.91K
VANGUARD GROUP INC
Shares:203.64K
Value:$301.39K
GEODE CAPITAL MANAGEMENT, LLC
Shares:136.44K
Value:$201.93K
Summary
Showing Top 3 of 30
About MIRA Pharmaceuticals, Inc.
https://mirapharmaceuticals.comMIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.32M ▼ | $-22.69M ▼ | 0% | $-1.18 ▼ | $-1.14M ▲ |
| Q2-2025 | $0 | $1.55M ▼ | $-1.54M ▲ | 0% | $-0.09 ▲ | $-1.55M ▲ |
| Q1-2025 | $0 | $1.81M ▼ | $-1.78M ▲ | 0% | $-0.11 ▲ | $-1.81M ▲ |
| Q4-2024 | $0 | $2.44M ▲ | $-2.4M ▼ | 0% | $-0.16 ▼ | $-2.44M ▼ |
| Q3-2024 | $0 | $2.08M | $-2.04M | 0% | $-0.14 | $0 |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.64M ▲ | $7.63M ▲ | $83.93K ▼ | $7.55M ▲ |
| Q2-2025 | $730.48K ▼ | $868.32K ▼ | $298.46K ▲ | $569.86K ▼ |
| Q1-2025 | $1.21M ▼ | $1.4M ▼ | $106.17K ▼ | $1.29M ▼ |
| Q4-2024 | $2.83M ▼ | $2.92M ▼ | $723.35K ▲ | $2.2M ▼ |
| Q3-2024 | $4.14M | $4.27M | $692.83K | $3.57M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-22.69M ▼ | $-1.1M ▼ | $0 | $3.01M ▲ | $1.91M ▲ | $-1.1M ▼ |
| Q2-2025 | $-1.54M ▲ | $-799.65K ▲ | $0 | $323.84K ▲ | $-475.81K ▲ | $-799.65K ▲ |
| Q1-2025 | $-1.78M ▲ | $-1.63M ▲ | $0 | $3.38K ▼ | $-1.63M ▼ | $-1.63M ▲ |
| Q4-2024 | $-2.4M ▼ | $-1.81M ▲ | $0 | $493.4K ▼ | $-1.31M ▼ | $-1.81M ▲ |
| Q3-2024 | $-2.04M | $-1.84M | $0 | $3.16M | $1.32M | $-1.84M |
CEO
Erez Aminov
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
CROSS STAFF INVESTMENTS INC
Shares:359.4K
Value:$531.91K
VANGUARD GROUP INC
Shares:203.64K
Value:$301.39K
GEODE CAPITAL MANAGEMENT, LLC
Shares:136.44K
Value:$201.93K
Summary
Showing Top 3 of 30